AbbVie Inc. (ABBV)
AbbVie Near Deal for Revolution Medicines
The cancer-drug biotech firm has a market value around $16 billion.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
What Can Trigger A Breakout In Abbvie Stock?
AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies surpassing 30% within comparable periods, including significant years such as 2017 and 2024.
AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw AbbVie (ABBV) settling at $220.18, representing a -3.98% change from its previous close.
AbbVie: Rocky Near-Term, Positive Long-Term
AbbVie outperformed the healthcare sector in 2025, but it remains to be seen whether the stock can repeat its performance in 2026. Last year, the stock was supported by relief for the pharmaceutical sector as MFN agreements were signed, its revenue growth was strong and earnings surpassed expectations. However, elevated forward P/E, potential MFN-driven profit pressure, and a market shift favoring cyclicals over defensives, can impact it negatively in 2026.
My Most Important Warning To Dividend Investors For 2026
The U.S. government is increasingly funding deficits with short-term debt, making interest expenses highly sensitive to Fed policy. A declining average maturity in the sovereign bond index tightens the link between fiscal and monetary policy, amplifying market complexity. Artificially subdued long-term bond supply likely keeps long-term yields lower than they would be with more balanced issuance.
Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth
ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.
AbbVie: Solid Growth, Some Risks, And An Attractive Setup In 2026
AbbVie earns a buy rating, with strong 2025 EPS growth driven by Skyrizi and Rinvoq, despite pipeline concerns and a higher P/E. ABBV's valuation remains attractive; a 14.4x FY 2027 multiple is compelling if earnings materialize, with technicals supporting a bullish breakout. Risks include Humira revenue erosion, pipeline uncertainty, and debt burden, but ABBV's clean loss-of-exclusivity profile and robust FCF yield support GARP status.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Best Dividend Aristocrats For January 2026
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.
3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains
Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.
Best Dividend Kings: December 2025
Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long-term expected annualized returns of at least 10%. Dividend growth for the Kings remains subdued at 5.81% for 2025, trailing the 2024 rate of 6.32%.
